This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matthai, W. H. Articles by Siegel, J. E. Search for Related Content PubMed PubMed Citation Articles by Matthai, W. H., Jr. Articles by Siegel, J. E.

Antithrombin activity during the period of percutaneous coronary revascularization

Relation to heparin use, thrombotic complications and restenosis

William H. Matthai, Jr., MD, FACC^*, Peter B. Kurnik, MD, FACC, William C. Groh, MD, FACC^*, William J. Untereker, MD, FACC^* and Jamie E. Siegel, MD

^* Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Department of Medicine, UMDNJ/Robert Wood Johnson Medical School at Camden, Camden, New Jersey, USA
Department of Medicine, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

View larger version (17K): [in a new window]   Figure 1 Mean antithrombin activity (±SD) for the patient sample at the four points at which antithrombin activity was determined. Mean AT activity at each time point was significantly different from every other time point.

View larger version (39K): [in a new window]   Figure 2 Percent with antithrombin activity <70% for the patient sample at the four points at which antithrombin activity was determined. The percentage of patients with AT <70% was significantly greater post-PTCR and the next morning than pre-PTCR. *p < 0.001 vs. Pre PTCR.

View larger version (15K): [in a new window]   Figure 3 Recovery of antithrombin activity from the time of heparin discontinuation. Antithrombin activity remained significantly less than normal until heparin had been discontinued for more than 20 h. *p < 0.05 vs. normal.